|
G |
Dek |
DEK proto-oncogene |
multiple interactions |
ISO |
DEK protein results in decreased chemical synthesis of and results in increased uptake of Pyrrolidonecarboxylic Acid |
CTD |
PMID:28558019 |
|
NCBI chr17:17,965,872...17,987,836
Ensembl chr17:17,965,881...17,987,834
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
[1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of Pyrrolidonecarboxylic Acid analog |
CTD |
PMID:26820058 |
|
NCBI chr 1:215,856,967...215,858,034
Ensembl chr 1:215,856,971...215,858,034
|
|
|
G |
Ace |
angiotensin I converting enzyme |
multiple interactions |
EXP |
Captopril inhibits the reaction [Pregabalin results in increased expression of ACE protein] |
CTD |
PMID:31629013 |
|
NCBI chr10:94,170,766...94,213,831
Ensembl chr10:94,170,766...94,187,822
|
|
G |
Ace2 |
angiotensin I converting enzyme 2 |
decreases response to substance multiple interactions |
ISO EXP |
ACE2 gene SNP results in decreased susceptibility to Captopril Captopril inhibits the reaction [Pregabalin results in decreased expression of ACE2 protein] |
CTD |
PMID:17473847 PMID:31629013 |
|
NCBI chr X:32,050,734...32,095,860
Ensembl chr X:32,049,931...32,096,016
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO EXP |
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; Captopril inhibits the reaction [AGT protein results in increased expression of ACTA2 protein] [goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of ACTA2 protein]; Captopril inhibits the reaction [Silicon Dioxide results in increased expression of ACTA2 protein] |
CTD |
PMID:31181250 |
|
NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
EXP ISO |
Captopril inhibits the reaction [Pregabalin results in decreased expression of AGT protein] Captopril inhibits the reaction [LEPR protein affects the expression of AGT protein] [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in decreased expression of GLI3 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in decreased expression of PTCH1 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of GLI1 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of GLI2 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of SHH protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of SMO protein]; Captopril inhibits the reaction [AGT protein results in increased expression of ACTA2 protein] |
CTD |
PMID:28130181 PMID:31181250 PMID:31629013 |
|
NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
multiple interactions |
EXP ISO |
Captopril inhibits the reaction [Pregabalin results in increased expression of AGTR1 protein] Captopril inhibits the reaction [LEPR protein affects the expression of AGTR1A mRNA] |
CTD |
PMID:28130181 PMID:31629013 |
|
NCBI chr17:35,907,102...35,958,136
Ensembl chr17:35,907,108...35,958,077
|
|
G |
Bdkrb2 |
bradykinin receptor B2 |
multiple interactions |
ISO |
Captopril inhibits the reaction [LEPR protein affects the expression of BDKRB2 protein] |
CTD |
PMID:28130181 |
|
NCBI chr 6:129,399,468...129,429,676
Ensembl chr 6:129,399,468...129,429,676
|
|
G |
Calb1 |
calbindin 1 |
multiple interactions |
ISO |
Captopril promotes the reaction [LEPR protein affects the expression of CALB1 protein] |
CTD |
PMID:28130181 |
|
NCBI chr 5:29,538,380...29,562,774
Ensembl chr 5:29,538,380...29,562,773
|
|
G |
Car2 |
carbonic anhydrase 2 |
multiple interactions |
ISO |
Captopril promotes the reaction [LEPR protein affects the expression of CAR2 mRNA] |
CTD |
PMID:28130181 |
|
NCBI chr 2:88,097,740...88,112,868
Ensembl chr 2:88,097,720...88,113,029
|
|
G |
Gli1 |
GLI family zinc finger 1 |
multiple interactions |
EXP ISO |
[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of GLI1 protein]; Captopril inhibits the reaction [Silicon Dioxide results in increased expression of GLI1 protein] [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of GLI1 protein] |
CTD |
PMID:31181250 |
|
NCBI chr 7:70,620,794...70,633,171
Ensembl chr 7:70,620,766...70,630,338
|
|
G |
Gli2 |
GLI family zinc finger 2 |
multiple interactions |
EXP ISO |
[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of GLI2 protein]; Captopril inhibits the reaction [Silicon Dioxide results in increased expression of GLI2 protein] [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of GLI2 protein] |
CTD |
PMID:31181250 |
|
NCBI chr13:34,829,021...35,049,172
Ensembl chr13:34,829,139...35,048,444
|
|
G |
Gli3 |
GLI family zinc finger 3 |
multiple interactions |
ISO EXP |
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in decreased expression of GLI3 protein] [goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in decreased expression of GLI3 protein]; Captopril inhibits the reaction [Silicon Dioxide results in decreased expression of GLI3 protein] |
CTD |
PMID:31181250 |
|
NCBI chr17:52,294,942...52,569,036
Ensembl chr17:52,294,942...52,569,036
|
|
G |
Lepr |
leptin receptor |
multiple interactions affects response to substance |
ISO |
Captopril inhibits the reaction [LEPR protein affects the expression of AGT protein]; Captopril inhibits the reaction [LEPR protein affects the expression of AGTR1A mRNA]; Captopril inhibits the reaction [LEPR protein affects the expression of BDKRB2 protein]; Captopril inhibits the reaction [LEPR protein affects the expression of PTH protein]; Captopril inhibits the reaction [LEPR protein affects the expression of VEGFA mRNA]; Captopril promotes the reaction [LEPR protein affects the expression of CALB1 protein]; Captopril promotes the reaction [LEPR protein affects the expression of CAR2 mRNA]; Captopril promotes the reaction [LEPR protein affects the expression of MMP9 mRNA]; Captopril promotes the reaction [LEPR protein affects the expression of RUNX2 mRNA]; Captopril promotes the reaction [LEPR protein affects the expression of VDR protein] LEPR protein affects the susceptibility to Captopril |
CTD |
PMID:28130181 |
|
NCBI chr 5:120,503,475...120,682,281
Ensembl chr 5:120,564,645...120,682,221
|
|
G |
Mas1 |
MAS1 proto-oncogene, G protein-coupled receptor |
multiple interactions |
EXP |
Captopril inhibits the reaction [Pregabalin results in decreased expression of MAS1 protein] |
CTD |
PMID:31629013 |
|
NCBI chr 1:48,076,761...48,108,218
Ensembl chr 1:48,077,033...48,108,216
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
Captopril promotes the reaction [LEPR protein affects the expression of MMP9 mRNA] |
CTD |
PMID:28130181 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Nppb |
natriuretic peptide B |
multiple interactions |
EXP |
Captopril inhibits the reaction [Pregabalin results in increased expression of NPPB protein] |
CTD |
PMID:31629013 |
|
NCBI chr 5:164,796,176...164,797,538
Ensembl chr 5:164,796,185...164,797,531
|
|
G |
Prkaca |
protein kinase cAMP-activated catalytic subunit alpha |
multiple interactions |
EXP |
Captopril inhibits the reaction [Pregabalin results in decreased expression of PRKACA protein] |
CTD |
PMID:31629013 |
|
NCBI chr19:25,095,089...25,118,869
Ensembl chr19:25,095,089...25,118,860
|
|
G |
Ptch1 |
patched 1 |
multiple interactions |
EXP ISO |
[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in decreased expression of PTCH1 protein]; Captopril inhibits the reaction [Silicon Dioxide results in decreased expression of PTCH1 protein] [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in decreased expression of PTCH1 protein] |
CTD |
PMID:31181250 |
|
NCBI chr17:1,032,242...1,085,885
Ensembl chr17:1,029,048...1,093,873
|
|
G |
Pth |
parathyroid hormone |
multiple interactions |
ISO |
Captopril inhibits the reaction [LEPR protein affects the expression of PTH protein] |
CTD |
PMID:28130181 |
|
NCBI chr 1:178,215,829...178,218,761
Ensembl chr 1:178,215,829...178,218,761
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
multiple interactions |
ISO |
Captopril promotes the reaction [LEPR protein affects the expression of RUNX2 mRNA] |
CTD |
PMID:28130181 |
|
NCBI chr 9:18,564,743...18,773,092
Ensembl chr 9:18,564,927...18,773,092
|
|
G |
Shh |
sonic hedgehog signaling molecule |
multiple interactions |
ISO EXP |
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of SHH protein] [goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of SHH protein]; Captopril inhibits the reaction [Silicon Dioxide results in increased expression of SHH protein] |
CTD |
PMID:31181250 |
|
NCBI chr 4:718,538...727,691
Ensembl chr 4:718,538...727,691
|
|
G |
Smo |
smoothened, frizzled class receptor |
multiple interactions |
ISO EXP |
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of SMO protein] [goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of SMO protein]; Captopril inhibits the reaction [Silicon Dioxide results in increased expression of SMO protein] |
CTD |
PMID:31181250 |
|
NCBI chr 4:57,019,941...57,041,779
Ensembl chr 4:57,019,941...57,042,770
|
|
G |
Vdr |
vitamin D receptor |
multiple interactions |
ISO |
Captopril promotes the reaction [LEPR protein affects the expression of VDR protein] |
CTD |
PMID:28130181 |
|
NCBI chr 7:139,344,452...139,394,138
Ensembl chr 7:139,342,063...139,394,166
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
Captopril inhibits the reaction [LEPR protein affects the expression of VEGFA mRNA] |
CTD |
PMID:28130181 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
increases expression multiple interactions |
ISO |
Clindamycin results in increased expression of CYP3A4 mRNA Clindamycin results in increased expression of and results in increased activity of CYP3A4 protein |
CTD |
PMID:18505790 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
increases expression |
ISO |
Clindamycin results in increased expression of MMP13 mRNA |
CTD |
PMID:20338993 |
|
NCBI chr 8:5,522,739...5,533,018
Ensembl chr 8:5,522,739...5,533,018
|
|
G |
RT1-Db1 |
RT1 class II, locus Db1 |
affects expression |
ISO |
Clindamycin affects the expression of HLA-DRB1 mRNA |
CTD |
PMID:25811541 |
|
NCBI chr20:4,087,621...4,097,190
Ensembl chr20:4,087,618...4,097,190
|
|
G |
RT1-S3 |
RT1 class Ib, locus S3 |
affects expression |
ISO |
Clindamycin affects the expression of HLA-E mRNA |
CTD |
PMID:25811541 |
|
NCBI chr20:3,176,124...3,180,825
Ensembl chr20:3,176,107...3,179,818
|
|
|
G |
Pon1 |
paraoxonase 1 |
decreases activity |
ISO |
clindamycin phosphate results in decreased activity of PON1 protein |
CTD |
PMID:16880604 |
|
NCBI chr 4:30,249,749...30,276,297
Ensembl chr 4:30,249,742...30,276,372
|
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression increases localization multiple interactions |
ISO |
domoic acid results in increased expression of BAX mRNA domoic acid results in increased localization of BAX protein Carbachol inhibits the reaction [domoic acid results in increased localization of BAX protein] |
CTD |
PMID:18293405 PMID:19200344 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
affects expression |
ISO |
domoic acid affects the expression of BCL2 mRNA |
CTD |
PMID:18293405 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity |
ISO |
Carbachol inhibits the reaction [domoic acid results in increased activity of CASP3 protein] |
CTD |
PMID:19200344 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression |
ISO |
domoic acid results in increased expression of GCLC mRNA; domoic acid results in increased expression of GCLC protein |
CTD |
PMID:23315585 |
|
NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression decreases response to substance affects response to substance |
ISO |
domoic acid results in increased expression of GCLM mRNA; domoic acid results in increased expression of GCLM protein [GCLM protein results in decreased susceptibility to domoic acid] which results in decreased susceptibility to 2,3-dimethoxy-1,4-naphthoquinone; [GCLM protein results in decreased susceptibility to domoic acid] which results in decreased susceptibility to Hydrogen Peroxide; GCLM protein results in decreased susceptibility to domoic acid; GCLM results in decreased susceptibility to domoic acid GCLM affects the susceptibility to domoic acid |
CTD |
PMID:17804861 PMID:19200344 PMID:23315585 |
|
NCBI chr 2:225,827,504...225,847,876
Ensembl chr 2:225,827,504...225,847,874
|
|
G |
Gria1 |
glutamate ionotropic receptor AMPA type subunit 1 |
increases phosphorylation |
EXP |
domoic acid results in increased phosphorylation of GRIA1 protein |
CTD |
PMID:19564213 |
|
NCBI chr10:42,441,723...42,760,200
Ensembl chr10:42,614,713...42,760,200
|
|
G |
Pvalb |
parvalbumin |
increases expression |
ISO |
domoic acid results in increased expression of PVALB protein |
CTD |
PMID:26797589 |
|
NCBI chr 7:119,428,657...119,443,674
Ensembl chr 7:119,429,019...119,441,487
|
|
G |
Wdr35 |
WD repeat domain 35 |
increases expression multiple interactions |
EXP |
domoic acid results in increased expression of WDR35 mRNA; domoic acid results in increased expression of WDR35 protein 2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline inhibits the reaction [domoic acid results in increased expression of WDR35 protein]; Edaravone inhibits the reaction [domoic acid results in increased expression of WDR35 protein] |
CTD |
PMID:23289926 |
|
NCBI chr 6:34,094,291...34,152,048
Ensembl chr 6:34,094,306...34,151,622
|
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
decreases response to substance |
ISO |
ABCC1 protein results in decreased susceptibility to Fosinopril |
CTD |
PMID:22095822 |
|
NCBI chr10:549,537...672,235
Ensembl chr10:549,883...672,196
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
decreases response to substance multiple interactions increases export |
ISO |
ABCC2 protein results in decreased susceptibility to Fosinopril ABCC2 protein affects the reaction [Fosinopril affects the export of Methotrexate] desloratadine inhibits the reaction [ABCC2 protein results in increased export of Fosinopril]; Loratadine inhibits the reaction [ABCC2 protein results in increased export of Fosinopril]; Methotrexate inhibits the reaction [ABCC2 protein results in increased export of Fosinopril] |
CTD |
PMID:22095822 |
|
NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
|
|
G |
Adipor2 |
adiponectin receptor 2 |
increases expression |
EXP |
fosinopril increases expression of adipor2 mRNA in rat liver |
RGD |
PMID:19076162 |
RGD:2307264 |
NCBI chr 4:151,412,135...151,480,108
Ensembl chr 4:151,414,684...151,428,894
|
|
G |
Afp |
alpha-fetoprotein |
multiple interactions |
ISO |
Fosinopril inhibits the reaction [Diethylnitrosamine results in increased expression of AFP protein] |
CTD |
PMID:29859236 |
|
NCBI chr14:19,141,755...19,159,919
Ensembl chr14:19,141,755...19,159,923
|
|
G |
Agt |
angiotensinogen |
decreases expression |
EXP |
Fosinopril results in decreased expression of AGT protein |
CTD |
PMID:12411096 |
|
NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
|
|
G |
Bmpr2 |
bone morphogenetic protein receptor type 2 |
multiple interactions |
EXP |
Fosinopril inhibits the reaction [Puromycin Aminonucleoside results in increased expression of BMPR2 mRNA] |
CTD |
PMID:17803470 |
|
NCBI chr 9:66,568,074...66,683,019
Ensembl chr 9:66,568,074...66,676,494
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
Fosinopril inhibits the reaction [Diethylnitrosamine results in increased expression of CCND1 mRNA] |
CTD |
PMID:29859236 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
Fosinopril inhibits the reaction [Diethylnitrosamine results in increased activity of GPT protein] |
CTD |
PMID:29859236 |
|
NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
|
|
G |
Kl |
Klotho |
increases expression |
EXP |
Fosinopril results in increased expression of KL mRNA; Fosinopril results in increased expression of KL protein |
CTD |
PMID:21051829 |
|
NCBI chr12:942,974...987,206
Ensembl chr12:943,006...987,551
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
Fosinopril inhibits the reaction [Diethylnitrosamine results in increased expression of MMP2 protein] |
CTD |
PMID:29859236 |
|
NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases expression multiple interactions |
EXP |
Fosinopril results in decreased expression of MMP9 mRNA; Fosinopril results in decreased expression of MMP9 protein [Valsartan co-treated with Fosinopril] results in decreased expression of MMP9 mRNA; [Valsartan co-treated with Fosinopril] results in decreased expression of MMP9 protein |
CTD |
PMID:21051829 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
Fosinopril inhibits the reaction [Diethylnitrosamine results in decreased expression of NFKB1 protein] |
CTD |
PMID:29859236 |
|
NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
|
|
G |
Nos3 |
nitric oxide synthase 3 |
affects expression |
EXP |
Fosinopril affects the expression of NOS3 mRNA; Fosinopril affects the expression of NOS3 protein |
CTD |
PMID:18209565 |
|
NCBI chr 4:7,321,908...7,342,404
Ensembl chr 4:7,320,668...7,342,410
|
|
G |
Pde1a |
phosphodiesterase 1A |
affects expression |
EXP |
Fosinopril affects the expression of PDE1A mRNA; Fosinopril affects the expression of PDE1A protein |
CTD |
PMID:18209565 |
|
NCBI chr 3:66,803,247...67,263,658
Ensembl chr 3:66,803,247...66,885,094
|
|
G |
Pde1c |
phosphodiesterase 1C |
affects expression |
EXP |
Fosinopril affects the expression of PDE1C mRNA; Fosinopril affects the expression of PDE1C protein |
CTD |
PMID:18209565 |
|
NCBI chr 4:86,359,762...86,925,044
Ensembl chr 4:86,359,820...86,630,543
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
Fosinopril inhibits the reaction [Diethylnitrosamine results in increased phosphorylation of RELA protein] |
CTD |
PMID:29859236 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Serpine1 |
serpin family E member 1 |
decreases expression multiple interactions |
EXP |
Fosinopril results in decreased expression of SERPINE1 mRNA; Fosinopril results in decreased expression of SERPINE1 protein [Valsartan co-treated with Fosinopril] results in decreased expression of SERPINE1 mRNA; [Valsartan co-treated with Fosinopril] results in decreased expression of SERPINE1 protein |
CTD |
PMID:21051829 |
|
NCBI chr12:22,641,104...22,651,482
Ensembl chr12:22,641,104...22,651,482
|
|
G |
Slc15a1 |
solute carrier family 15 member 1 |
multiple interactions |
ISO |
Fosinopril inhibits the reaction [SLC15A1 protein results in increased uptake of glycylsarcosine] |
CTD |
PMID:18713951 |
|
NCBI chr15:106,800,081...106,844,668
Ensembl chr15:106,800,081...106,844,426
|
|
G |
Slc15a2 |
solute carrier family 15 member 2 |
multiple interactions |
EXP |
Fosinopril inhibits the reaction [SLC15A2 protein results in increased uptake of glycylsarcosine] |
CTD |
PMID:18713951 |
|
NCBI chr11:66,932,664...66,961,708
Ensembl chr11:66,932,614...66,961,713
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
Fosinopril inhibits the reaction [Diethylnitrosamine results in increased expression of TGFB1 protein] |
CTD |
PMID:29859236 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
decreases expression multiple interactions |
EXP |
Fosinopril results in decreased expression of TIMP1 mRNA; Fosinopril results in decreased expression of TIMP1 protein [Valsartan co-treated with Fosinopril] results in decreased expression of TIMP1 mRNA; [Valsartan co-treated with Fosinopril] results in decreased expression of TIMP1 protein |
CTD |
PMID:21051829 |
|
NCBI chr X:1,364,771...1,369,451
Ensembl chr X:1,364,786...1,369,384
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
Fosinopril inhibits the reaction [Diethylnitrosamine results in increased expression of TNF protein] |
CTD |
PMID:29859236 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
Fosinopril inhibits the reaction [Diethylnitrosamine results in increased expression of VEGFA protein] |
CTD |
PMID:29859236 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression |
EXP |
Kainic Acid results in increased expression of ABCB1A mRNA; Kainic Acid results in increased expression of ABCB1A protein |
CTD |
PMID:14706787 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcb1b |
ATP-binding cassette, subfamily B (MDR/TAP), member 1B |
increases expression |
EXP |
Kainic Acid results in increased expression of ABCB1B mRNA; Kainic Acid results in increased expression of ABCB1B protein |
CTD |
PMID:14706787 |
|
NCBI chr 4:22,225,123...22,307,577
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
increases expression |
ISO |
Kainic Acid results in increased expression of ABCG2 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
|
|
G |
Aco2 |
aconitase 2 |
multiple interactions decreases activity |
EXP |
6-Cyano-7-nitroquinoxaline-2,3-dione inhibits the reaction [Kainic Acid results in decreased activity of ACO2 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Kainic Acid results in decreased activity of ACO2 protein] |
CTD |
PMID:11520895 |
|
NCBI chr 7:123,102,493...123,145,608
Ensembl chr 7:123,102,468...123,145,635
|
|
G |
Acp1 |
acid phosphatase 1 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of ACP1 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 6:49,836,064...49,851,714
Ensembl chr 6:49,836,075...49,851,714
|
|
G |
Adk |
adenosine kinase |
increases expression |
ISO |
Kainic Acid results in increased expression of ADK mRNA |
CTD |
PMID:17997037 |
|
NCBI chr15:3,033,535...3,435,888
Ensembl chr15:3,033,495...3,435,888
|
|
G |
Adnp |
activity-dependent neuroprotector homeobox |
multiple interactions decreases expression |
EXP |
Enzyme Inhibitors inhibits the reaction [Kainic Acid results in decreased expression of ADNP protein] Kainic Acid results in decreased expression of ADNP mRNA; Kainic Acid results in decreased expression of ADNP protein |
CTD |
PMID:18375135 |
|
NCBI chr 3:164,937,188...164,964,819
Ensembl chr 3:164,937,198...164,964,702
|
|
G |
Adra1b |
adrenoceptor alpha 1B |
increases response to substance |
ISO |
ADRA1B protein results in increased susceptibility to Kainic Acid |
CTD |
PMID:19125850 |
|
NCBI chr10:29,392,762...29,450,644
Ensembl chr10:29,392,762...29,450,644
|
|
G |
Aif1 |
allograft inflammatory factor 1 |
increases expression multiple interactions |
EXP |
Kainic Acid results in increased expression of AIF1 protein NADP inhibits the reaction [Kainic Acid results in increased expression of AIF1 protein] |
CTD |
PMID:32057834 |
|
NCBI chr20:5,161,350...5,167,176
Ensembl chr20:5,161,333...5,166,448
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
increases localization multiple interactions |
ISO |
Kainic Acid results in increased localization of AIFM1 protein Minocycline inhibits the reaction [Kainic Acid results in increased localization of AIFM1 protein] |
CTD |
PMID:16469440 |
|
NCBI chr X:135,304,063...135,343,062
Ensembl chr X:135,304,066...135,343,087
|
|
G |
Alox5ap |
arachidonate 5-lipoxygenase activating protein |
increases expression |
EXP |
Kainic Acid results in increased expression of ALOX5AP mRNA |
CTD |
PMID:19700661 |
|
NCBI chr12:6,854,930...6,879,112
Ensembl chr12:6,854,920...6,879,154
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
increases expression |
ISO |
Kainic Acid results in increased expression of APAF1 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 7:31,699,309...31,784,192
Ensembl chr 7:31,699,885...31,784,192
|
|
G |
Apex1 |
apurinic/apyrimidinic endodeoxyribonuclease 1 |
multiple interactions |
EXP |
[Raloxifene Hydrochloride co-treated with Kainic Acid] results in increased expression of APEX1 mRNA |
CTD |
PMID:16120186 |
|
NCBI chr15:27,849,943...27,852,083
Ensembl chr15:27,849,979...27,852,082
|
|
G |
Apoe |
apolipoprotein E |
decreases expression |
ISO |
Kainic Acid results in decreased expression of APOE mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 1:80,612,894...80,616,820
Ensembl chr 1:80,612,895...80,617,057
|
|
G |
Arc |
activity-regulated cytoskeleton-associated protein |
increases expression |
EXP ISO |
Kainic Acid results in increased expression of ARC mRNA; Kainic Acid results in increased expression of ARC protein |
CTD |
PMID:17632064 PMID:30557575 |
|
NCBI chr 7:115,907,097...115,911,059
Ensembl chr 7:115,907,097...115,910,541
|
|
G |
Atf7ip |
activating transcription factor 7 interacting protein |
decreases expression |
EXP |
Kainic Acid results in decreased expression of ATF7IP mRNA |
CTD |
PMID:19700661 |
|
NCBI chr 4:170,476,998...170,563,063
Ensembl chr 4:170,518,673...170,559,532
|
|
G |
Atg5 |
autophagy related 5 |
multiple interactions increases expression |
EXP |
NADP inhibits the reaction [Kainic Acid results in increased expression of ATG5 protein] |
CTD |
PMID:32057834 |
|
NCBI chr20:49,301,783...49,393,147
Ensembl chr20:49,318,308...49,393,140
|
|
G |
B4galt2 |
beta-1,4-galactosyltransferase 2 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of B4GALT2 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 5:136,707,510...136,717,345
Ensembl chr 5:136,707,510...136,715,981
|
|
G |
Bag3 |
BAG cochaperone 3 |
increases expression |
EXP |
Kainic Acid results in increased expression of BAG3 mRNA |
CTD |
PMID:19700661 |
|
NCBI chr 1:199,941,258...199,965,191
Ensembl chr 1:199,941,161...199,965,191
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
EXP ISO |
Kainic Acid results in increased expression of BAX mRNA; Kainic Acid results in increased expression of BAX protein oridonin inhibits the reaction [Kainic Acid results in increased expression of BAX mRNA] EPO protein inhibits the reaction [Kainic Acid results in increased expression of BAX protein]; EPOR protein promotes the reaction [EPO protein inhibits the reaction [Kainic Acid results in increased expression of BAX protein]] Valproic Acid inhibits the reaction [Kainic Acid results in increased expression of BAX protein] |
CTD |
PMID:18711747 PMID:19700661 PMID:25453207 PMID:31430510 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
ISO EXP |
4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione inhibits the reaction [Kainic Acid results in decreased expression of BCL2 protein]; 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione promotes the reaction [Valproic Acid inhibits the reaction [Kainic Acid results in decreased expression of BCL2 protein]]; Valproic Acid inhibits the reaction [Kainic Acid results in decreased expression of BCL2 protein] Kainic Acid results in decreased expression of BCL2 mRNA oridonin inhibits the reaction [Kainic Acid results in decreased expression of BCL2 mRNA] |
CTD |
PMID:25453207 PMID:31430510 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions increases expression |
EXP |
[Curcumin co-treated with Manganese] inhibits the reaction [Kainic Acid results in increased expression of BDNF mRNA]; [diacetylcurcumin co-treated with Manganese] inhibits the reaction [Kainic Acid results in increased expression of BDNF mRNA] Kainic Acid results in increased expression of BDNF mRNA; Kainic Acid results in increased expression of BDNF protein |
CTD |
PMID:1641125 PMID:9073163 PMID:11279263 PMID:16166269 PMID:17827730 PMID:19700661 |
|
NCBI chr 3:100,768,637...100,819,216
Ensembl chr 3:100,768,637...100,819,210
|
|
G |
Becn1 |
beclin 1 |
multiple interactions increases expression |
EXP |
NADP inhibits the reaction [Kainic Acid results in increased expression of BECN1 protein] |
CTD |
PMID:32057834 |
|
NCBI chr10:89,209,944...89,225,297
Ensembl chr10:89,209,940...89,225,297
|
|
G |
C1qb |
complement C1q B chain |
increases expression |
ISO |
Kainic Acid results in increased expression of C1QB mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 5:155,246,444...155,251,995
Ensembl chr 5:155,246,447...155,252,003
|
|
G |
C4b |
complement C4B (Chido blood group) |
increases expression |
ISO |
Kainic Acid results in increased expression of C4B mRNA |
CTD |
PMID:17997037 |
|
NCBI chr20:4,302,344...4,316,752
Ensembl chr20:4,302,344...4,316,715
|
|
G |
Calb1 |
calbindin 1 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of CALB1 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 5:29,538,380...29,562,774
Ensembl chr 5:29,538,380...29,562,773
|
|
G |
Camk4 |
calcium/calmodulin-dependent protein kinase IV |
decreases expression |
ISO |
Kainic Acid results in decreased expression of CAMK4 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr18:25,746,878...25,975,962
Ensembl chr18:25,749,098...25,965,957
|
|
G |
Capns1 |
calpain, small subunit 1 |
increases expression |
EXP |
Kainic Acid results in increased expression of CAPNS1 mRNA |
CTD |
PMID:19700661 |
|
NCBI chr 1:91,058,528...91,064,880
|
|
G |
Casp3 |
caspase 3 |
increases activity multiple interactions increases cleavage increases expression |
ISO EXP |
Kainic Acid results in increased activity of CASP3 protein oridonin inhibits the reaction [Kainic Acid results in increased activity of CASP3 protein] EPO protein inhibits the reaction [Kainic Acid results in increased expression of CASP3 protein] Kainic Acid results in increased cleavage of CASP3 protein Kainic Acid results in increased expression of CASP3 mRNA; Kainic Acid results in increased expression of CASP3 protein 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione inhibits the reaction [Kainic Acid results in increased cleavage of CASP3 protein]; 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione promotes the reaction [Valproic Acid inhibits the reaction [Kainic Acid results in increased cleavage of CASP3 protein]]; Minocycline inhibits the reaction [Kainic Acid results in increased activity of CASP3 protein]; Valproic Acid inhibits the reaction [Kainic Acid results in increased cleavage of CASP3 protein] |
CTD |
PMID:16469440 PMID:18711747 PMID:19700661 PMID:25453207 PMID:31430510 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Cat |
catalase |
decreases expression decreases activity multiple interactions |
ISO EXP |
Kainic Acid results in decreased expression of CAT mRNA; Kainic Acid results in decreased expression of CAT protein Kainic Acid results in decreased activity of CAT protein oridonin inhibits the reaction [Kainic Acid results in decreased activity of CAT protein] |
CTD |
PMID:29208536 PMID:31430510 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Cck |
cholecystokinin |
decreases expression |
EXP |
Kainic Acid results in decreased expression of CCK protein |
CTD |
PMID:7774662 |
|
NCBI chr 8:130,120,525...130,127,515
Ensembl chr 8:130,120,523...130,127,392
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression |
EXP |
Kainic Acid results in increased expression of CCL2 mRNA |
CTD |
PMID:19700661 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccne1 |
cyclin E1 |
increases expression |
EXP |
Kainic Acid results in increased expression of CCNE1 protein |
CTD |
PMID:12941380 |
|
NCBI chr 1:94,485,830...94,495,112
Ensembl chr 1:94,485,832...94,494,980
|
|
G |
Cd68 |
Cd68 molecule |
increases expression |
EXP |
Kainic Acid results in increased expression of CD68 mRNA |
CTD |
PMID:19700661 |
|
NCBI chr10:56,268,726...56,270,605
Ensembl chr10:56,268,720...56,270,640
|
|
G |
Cdc42 |
cell division cycle 42 |
increases expression |
EXP |
Kainic Acid results in increased expression of CDC42 mRNA |
CTD |
PMID:19700661 |
|
NCBI chr 5:155,690,267...155,728,385
Ensembl chr 5:155,691,390...155,728,300
|
|
G |
Cdh13 |
cadherin 13 |
increases expression |
ISO |
Kainic Acid results in increased expression of CDH13 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr19:50,848,793...51,971,618
Ensembl chr19:50,848,736...51,972,103
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
increases expression |
EXP |
Kainic Acid results in increased expression of CDK2 protein |
CTD |
PMID:12941380 |
|
NCBI chr 7:3,124,953...3,132,533
Ensembl chr 7:3,124,954...3,132,457
|
|
G |
Ceacam1 |
CEA cell adhesion molecule 1 |
increases expression |
ISO |
Kainic Acid results in increased expression of CEACAM1 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 1:82,327,955...82,344,345
Ensembl chr 1:82,327,955...82,344,345
|
|
G |
Chgb |
chromogranin B |
increases expression |
EXP |
Kainic Acid results in increased expression of CHGB mRNA |
CTD |
PMID:9427505 |
|
NCBI chr 3:125,428,050...125,441,601
Ensembl chr 3:125,428,260...125,441,594
|
|
G |
Cited2 |
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 |
increases expression |
EXP |
Kainic Acid results in increased expression of CITED2 mRNA |
CTD |
PMID:19700661 |
|
NCBI chr 1:12,823,363...12,825,806
Ensembl chr 1:12,823,363...12,825,786
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
increases expression |
EXP |
Kainic Acid results in increased expression of CNR1 mRNA |
CTD |
PMID:22079489 |
|
NCBI chr 5:49,307,584...49,333,064
Ensembl chr 5:49,311,030...49,333,056
|
|
G |
Cnrip1 |
cannabinoid receptor interacting protein 1 |
increases expression |
EXP |
Kainic Acid results in increased expression of CNRIP1 mRNA |
CTD |
PMID:22079489 |
|
NCBI chr14:100,217,547...100,247,235
Ensembl chr14:100,217,289...100,247,235
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
increases expression |
ISO |
Kainic Acid results in increased expression of COL1A1 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
|
|
G |
Crhr1 |
corticotropin releasing hormone receptor 1 |
increases expression |
EXP |
Kainic Acid results in increased expression of CRHR1 mRNA |
CTD |
PMID:12093084 |
|
NCBI chr10:92,191,473...92,233,662
Ensembl chr10:92,191,718...92,232,645
|
|
G |
Ctsb |
cathepsin B |
multiple interactions increases expression |
EXP |
NADP inhibits the reaction [Kainic Acid results in increased expression of CTSB protein] |
CTD |
PMID:32057834 |
|
NCBI chr15:46,316,741...46,337,613
Ensembl chr15:46,316,741...46,337,612
|
|
G |
Ctsd |
cathepsin D |
multiple interactions increases expression |
EXP |
NADP inhibits the reaction [Kainic Acid results in increased expression of CTSD protein] |
CTD |
PMID:32057834 |
|
NCBI chr 1:215,541,570...215,553,446
Ensembl chr 1:215,541,542...215,553,451
|
|
G |
Ctss |
cathepsin S |
increases expression |
ISO |
Kainic Acid results in increased expression of CTSS mRNA; Kainic Acid results in increased expression of CTSS protein |
CTD |
PMID:17997037 |
|
NCBI chr 2:197,655,780...197,679,768
Ensembl chr 2:197,655,786...197,679,458
|
|
G |
Ctsz |
cathepsin Z |
increases expression |
ISO |
Kainic Acid results in increased expression of CTSZ mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 3:172,527,107...172,537,877
Ensembl chr 3:172,527,107...172,537,877
|
|
G |
Cycs |
cytochrome c, somatic |
increases localization multiple interactions increases expression |
ISO EXP |
Kainic Acid results in increased localization of CYCS protein Minocycline inhibits the reaction [Kainic Acid results in increased localization of CYCS protein] Kainic Acid results in increased expression of CYCS mRNA |
CTD |
PMID:16469440 PMID:19700661 |
|
NCBI chr 4:80,331,226...80,333,326
Ensembl chr 4:80,331,227...80,333,326
|
|
G |
Dgcr6 |
DiGeorge syndrome critical region gene 6 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of DGCR6 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr11:87,076,205...87,081,306
Ensembl chr11:87,076,381...87,081,950
|
|
G |
Dhx36 |
DEAH-box helicase 36 |
increases expression |
ISO |
Kainic Acid results in increased expression of DHX36 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 2:152,785,844...152,824,549
Ensembl chr 2:152,785,844...152,824,547
|
|
G |
Diablo |
diablo, IAP-binding mitochondrial protein |
increases expression |
EXP |
Kainic Acid results in increased expression of DIABLO mRNA |
CTD |
PMID:19700661 |
|
NCBI chr12:38,490,230...38,503,344
Ensembl chr12:38,490,230...38,503,330
|
|
G |
Drd2 |
dopamine receptor D2 |
decreases response to substance |
ISO |
DRD2 protein results in decreased susceptibility to Kainic Acid |
CTD |
PMID:11860278 |
|
NCBI chr 8:53,678,777...53,743,643
Ensembl chr 8:53,678,777...53,743,642
|
|
G |
Egr1 |
early growth response 1 |
decreases expression affects expression |
ISO EXP |
Kainic Acid results in decreased expression of EGR1 mRNA Kainic Acid affects the expression of EGR1 mRNA |
CTD |
PMID:17997037 PMID:19700661 |
|
NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
|
|
G |
Eif4a3 |
eukaryotic translation initiation factor 4A3 |
increases expression |
EXP |
Kainic Acid results in increased expression of EIF4A3 protein |
CTD |
PMID:17632064 |
|
NCBI chr10:108,415,201...108,425,195
Ensembl chr10:108,415,202...108,425,206
|
|
G |
Emc3 |
ER membrane protein complex subunit 3 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of EMC3 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 4:145,471,466...145,487,375
Ensembl chr 4:145,471,454...145,487,426
|
|
G |
En2 |
engrailed homeobox 2 |
affects response to substance decreases expression |
ISO |
EN2 protein affects the susceptibility to Kainic Acid Kainic Acid results in decreased expression of EN2 mRNA |
CTD |
PMID:19186208 |
|
NCBI chr 4:438,668...444,508
Ensembl chr 4:438,668...444,501
|
|
G |
Enc1 |
ectodermal-neural cortex 1 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of ENC1 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 2:28,049,217...28,061,023
Ensembl chr 2:28,049,217...28,061,029
|
|
G |
Epo |
erythropoietin |
multiple interactions |
ISO |
EPO protein inhibits the reaction [Kainic Acid results in decreased expression of EPOR protein]; EPO protein inhibits the reaction [Kainic Acid results in decreased expression of JAK2 protein]; EPO protein inhibits the reaction [Kainic Acid results in increased expression of BAX protein]; EPO protein inhibits the reaction [Kainic Acid results in increased expression of CASP3 protein]; EPO protein inhibits the reaction [Kainic Acid results in increased expression of GFAP protein]; EPOR protein promotes the reaction [EPO protein inhibits the reaction [Kainic Acid results in decreased expression of EPOR protein]]; EPOR protein promotes the reaction [EPO protein inhibits the reaction [Kainic Acid results in decreased expression of JAK2 protein]]; EPOR protein promotes the reaction [EPO protein inhibits the reaction [Kainic Acid results in increased expression of BAX protein]] |
CTD |
PMID:18711747 |
|
NCBI chr12:22,274,828...22,278,268
Ensembl chr12:22,274,828...22,278,266
|
|
G |
Epor |
erythropoietin receptor |
multiple interactions decreases expression |
ISO EXP |
EPO protein inhibits the reaction [Kainic Acid results in decreased expression of EPOR protein]; EPOR protein promotes the reaction [EPO protein inhibits the reaction [Kainic Acid results in decreased expression of EPOR protein]]; EPOR protein promotes the reaction [EPO protein inhibits the reaction [Kainic Acid results in decreased expression of JAK2 protein]]; EPOR protein promotes the reaction [EPO protein inhibits the reaction [Kainic Acid results in increased expression of BAX protein]] |
CTD |
PMID:18711747 |
|
NCBI chr 8:22,969,737...22,974,468
Ensembl chr 8:22,969,745...22,974,321
|
|
G |
Etfb |
electron transfer flavoprotein subunit beta |
decreases expression |
ISO |
Kainic Acid results in decreased expression of ETFB mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 1:98,472,776...98,486,940
Ensembl chr 1:98,472,745...98,486,976
|
|
G |
Fbxw5 |
F-box and WD repeat domain containing 5 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of FBXW5 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 3:2,726,705...2,731,213
Ensembl chr 3:2,727,254...2,731,212
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
increases expression |
EXP |
Kainic Acid results in increased expression of FGF2 mRNA |
CTD |
PMID:7649223 |
|
NCBI chr 2:124,081,072...124,134,133
Ensembl chr 2:124,081,072...124,134,681
|
|
G |
Fgf5 |
fibroblast growth factor 5 |
increases expression |
EXP |
Kainic Acid results in increased expression of FGF5 mRNA |
CTD |
PMID:7649223 |
|
NCBI chr14:12,974,921...12,996,046
Ensembl chr14:12,974,921...12,995,584
|
|
G |
Fgfr1 |
Fibroblast growth factor receptor 1 |
increases expression |
EXP |
Kainic Acid results in increased expression of FGFR1 mRNA |
CTD |
PMID:7649223 |
|
NCBI chr16:71,265,390...71,319,046
Ensembl chr16:71,266,248...71,319,449
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression decreases expression |
ISO EXP |
10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone inhibits the reaction [Valproic Acid inhibits the reaction [Kainic Acid results in increased expression of FOS protein]]; [Kainic Acid co-treated with dihydroxyethyldithiocarbamate] results in increased expression of FOS protein; Dizocilpine Maleate inhibits the reaction [[Kainic Acid co-treated with dihydroxyethyldithiocarbamate] results in increased expression of FOS protein]; Valproic Acid inhibits the reaction [Kainic Acid results in increased expression of FOS protein] Kainic Acid results in increased expression of FOS mRNA; Kainic Acid results in increased expression of FOS protein [Curcumin co-treated with Manganese] inhibits the reaction [Kainic Acid results in increased expression of FOS protein]; [diacetylcurcumin co-treated with Manganese] inhibits the reaction [Kainic Acid results in increased expression of FOS protein]; [Phenytoin co-treated with Drugs, Chinese Herbal] inhibits the reaction [Kainic Acid results in increased expression of FOS mRNA]; Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of FOS mRNA]; Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of FOS protein]; Diazepam inhibits the reaction [Kainic Acid results in increased expression of FOS protein]; dimemorfan inhibits the reaction [Kainic Acid results in increased expression of FOS mRNA]; dimemorfan inhibits the reaction [Kainic Acid results in increased expression of FOS protein]; N-(2-(3,4-Dichlorphenyl)ethyl)-N,N',N'-trimethyl-1,2-ethandiamin inhibits the reaction [Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of FOS mRNA]]; N-(2-(3,4-Dichlorphenyl)ethyl)-N,N',N'-trimethyl-1,2-ethandiamin inhibits the reaction [Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of FOS protein]]; N-(2-(3,4-Dichlorphenyl)ethyl)-N,N',N'-trimethyl-1,2-ethandiamin inhibits the reaction [dimemorfan inhibits the reaction [Kainic Acid results in increased expression of FOS mRNA]]; N-(2-(3,4-Dichlorphenyl)ethyl)-N,N',N'-trimethyl-1,2-ethandiamin inhibits the reaction [dimemorfan inhibits the reaction [Kainic Acid results in increased expression of FOS protein]]; Pentobarbital inhibits the reaction [Kainic Acid results in increased expression of FOS protein]; SIGMAR1 protein affects the reaction [Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of FOS mRNA]]; SIGMAR1 protein affects the reaction [Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of FOS protein]]; SIGMAR1 protein affects the reaction [dimemorfan inhibits the reaction [Kainic Acid results in increased expression of FOS mRNA]]; SIGMAR1 protein affects the reaction [dimemorfan inhibits the reaction [Kainic Acid results in increased expression of FOS protein]]; Valproic Acid inhibits the reaction [Kainic Acid results in increased expression of FOS protein] Kainic Acid results in decreased expression of FOS mRNA |
CTD |
PMID:7655348 PMID:7887109 PMID:8417141 PMID:8758711 PMID:15723099 PMID:16686654 PMID:17827730 PMID:17997037 PMID:26348896 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Fosl2 |
FOS like 2, AP-1 transcription factor subunit |
increases expression |
EXP |
Kainic Acid results in increased expression of FOSL2 mRNA |
CTD |
PMID:19700661 |
|
NCBI chr 6:25,598,936...25,616,995
Ensembl chr 6:25,598,936...25,616,995
|
|
G |
Fxyd1 |
FXYD domain-containing ion transport regulator 1 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of FXYD1 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 1:89,484,197...89,488,279
Ensembl chr 1:89,484,199...89,488,223
|
|
G |
Gabrb1 |
gamma-aminobutyric acid type A receptor subunit beta1 |
increases expression multiple interactions |
ISO |
Kainic Acid results in increased expression of GABRB1 mRNA Quercetin inhibits the reaction [Kainic Acid results in increased expression of GABRB1 mRNA] |
CTD |
PMID:27386150 |
|
NCBI chr14:38,631,192...39,112,598
Ensembl chr14:38,643,385...39,112,600
|
|
G |
Gabrb3 |
gamma-aminobutyric acid type A receptor subunit beta 3 |
multiple interactions increases expression |
ISO |
Quercetin inhibits the reaction [Kainic Acid results in increased expression of GABRB3 mRNA] |
CTD |
PMID:27386150 |
|
NCBI chr 1:113,034,251...113,265,364
Ensembl chr 1:112,976,770...113,265,364
|
|
G |
Gad1 |
glutamate decarboxylase 1 |
increases expression |
EXP |
Kainic Acid results in increased expression of GAD1 mRNA |
CTD |
PMID:16797850 |
|
NCBI chr 3:56,861,440...56,902,139
Ensembl chr 3:56,861,396...56,902,157
|
|
G |
Gad2 |
glutamate decarboxylase 2 |
increases expression |
EXP |
Kainic Acid results in increased expression of GAD2 mRNA |
CTD |
PMID:16797850 |
|
NCBI chr17:89,171,576...89,234,770
Ensembl chr17:89,171,250...89,238,040
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
increases expression |
EXP |
Kainic Acid results in increased expression of GADD45A mRNA; Kainic Acid results in increased expression of GADD45A protein |
CTD |
PMID:20955365 |
|
NCBI chr 4:97,782,512...97,784,814
Ensembl chr 4:97,782,512...97,784,842
|
|
G |
Gadd45b |
growth arrest and DNA-damage-inducible, beta |
decreases expression |
ISO |
Kainic Acid results in decreased expression of GADD45B mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 7:11,646,283...11,648,338
Ensembl chr 7:11,646,269...11,648,322
|
|
G |
Gadd45g |
growth arrest and DNA-damage-inducible, gamma |
decreases expression |
ISO |
Kainic Acid results in decreased expression of GADD45G mRNA |
CTD |
PMID:17997037 |
|
NCBI chr17:13,391,474...13,393,219
Ensembl chr17:13,391,467...13,393,243
|
|
G |
Gap43 |
growth associated protein 43 |
multiple interactions increases expression |
EXP |
Dizocilpine Maleate inhibits the reaction [Kainic Acid results in increased expression of GAP43 mRNA]; Pentobarbital inhibits the reaction [Kainic Acid results in increased expression of GAP43 mRNA] |
CTD |
PMID:8774942 |
|
NCBI chr11:58,624,198...58,717,916
Ensembl chr11:58,624,198...58,717,914
|
|
G |
Gcnt2 |
glucosaminyl (N-acetyl) transferase 2 (I blood group) |
increases expression |
ISO |
Kainic Acid results in increased expression of GCNT2 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr17:21,634,546...21,677,477
Ensembl chr17:21,634,551...21,739,408
|
|
G |
Gfap |
glial fibrillary acidic protein |
increases expression multiple interactions |
EXP ISO |
Kainic Acid results in increased expression of GFAP mRNA; Kainic Acid results in increased expression of GFAP protein NADP inhibits the reaction [Kainic Acid results in increased expression of GFAP protein] EPO protein inhibits the reaction [Kainic Acid results in increased expression of GFAP protein] PTGS2 affects the reaction [Kainic Acid results in increased expression of GFAP mRNA] |
CTD |
PMID:17997037 PMID:18711747 PMID:19700661 PMID:21589914 PMID:22790971 PMID:32057834 |
|
NCBI chr10:90,990,762...90,999,435
Ensembl chr10:90,990,762...90,999,506
|
|
G |
Glul |
glutamate-ammonia ligase |
multiple interactions decreases expression |
EXP |
oridonin inhibits the reaction [Kainic Acid results in decreased expression of GLUL mRNA] |
CTD |
PMID:31430510 |
|
NCBI chr13:71,331,052...71,340,207
Ensembl chr13:71,331,052...71,340,229
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of GPX1 protein |
CTD |
PMID:29208536 |
|
NCBI chr 8:117,117,430...117,118,528
Ensembl chr 8:117,117,430...117,118,522
|
|
G |
Gria1 |
glutamate ionotropic receptor AMPA type subunit 1 |
multiple interactions decreases expression |
EXP ISO |
2-(2-(4-(4-nitrobenzyloxy)phenyl)ethyl)isothiourea methanesulfonate inhibits the reaction [Kainic Acid results in decreased expression of GRIA1 protein]; Kainic Acid binds to and results in increased activity of GRIA1 protein; Urethane inhibits the reaction [Kainic Acid binds to and results in increased activity of GRIA1 protein] Kainic Acid results in decreased expression of GRIA1 mRNA Celecoxib promotes the reaction [Kainic Acid results in decreased expression of GRIA1 mRNA]; PTGS2 affects the reaction [Kainic Acid results in decreased expression of GRIA1 mRNA] Kainic Acid results in decreased expression of GRIA1 mRNA; Kainic Acid results in decreased expression of GRIA1 protein |
CTD |
PMID:7529610 PMID:11812690 PMID:17585341 PMID:21589914 |
|
NCBI chr10:42,441,723...42,760,200
Ensembl chr10:42,614,713...42,760,200
|
|
G |
Gria2 |
glutamate ionotropic receptor AMPA type subunit 2 |
multiple interactions increases methylation decreases expression affects response to substance |
EXP ISO |
Kainic Acid binds to and results in increased activity of GRIA2 protein; Urethane inhibits the reaction [Kainic Acid binds to and results in increased activity of GRIA2 protein] Kainic Acid results in increased methylation of GRIA2 gene Kainic Acid results in decreased expression of GRIA2 mRNA Celecoxib promotes the reaction [Kainic Acid results in decreased expression of GRIA2 mRNA]; RG108 inhibits the reaction [Kainic Acid results in increased methylation of GRIA2 gene] GRIA2 protein affects the susceptibility to Kainic Acid |
CTD |
PMID:7529610 PMID:10551584 PMID:11812690 PMID:21589914 PMID:24098468 |
|
NCBI chr 2:179,584,302...179,704,629
Ensembl chr 2:179,584,308...179,704,629
|
|
G |
Gria3 |
glutamate ionotropic receptor AMPA type subunit 3 |
decreases expression multiple interactions increases expression |
EXP ISO |
Kainic Acid results in decreased expression of GRIA3 mRNA celecoxib promotes the reaction [Kainic Acid results in decreased expression of GRIA3 mRNA] Kainic Acid results in increased expression of GRIA3 mRNA |
CTD |
PMID:7529610 PMID:21589914 |
|
NCBI chr X:127,561,843...127,829,763
Ensembl chr X:127,562,660...127,829,753
|
|
G |
Gria4 |
glutamate ionotropic receptor AMPA type subunit 4 |
decreases expression multiple interactions |
ISO |
Kainic Acid results in decreased expression of GRIA4 mRNA celecoxib promotes the reaction [Kainic Acid results in decreased expression of GRIA4 mRNA] |
CTD |
PMID:21589914 |
|
NCBI chr 8:1,548,145...2,045,874
Ensembl chr 8:1,548,146...2,045,817
|
|
G |
Grik1 |
glutamate ionotropic receptor kainate type subunit 1 |
decreases expression increases expression multiple interactions |
ISO |
Kainic Acid results in decreased expression of GRIK1 mRNA Kainic Acid results in increased expression of GRIK1 mRNA Celecoxib promotes the reaction [Kainic Acid results in decreased expression of GRIK1 mRNA]; PTGS2 affects the reaction [Kainic Acid results in decreased expression of GRIK1 mRNA] |
CTD |
PMID:21589914 PMID:29208536 |
|
NCBI chr11:27,811,954...28,213,940
Ensembl chr11:27,811,957...27,971,359
|
|
G |
Grik2 |
glutamate ionotropic receptor kainate type subunit 2 |
increases expression multiple interactions |
ISO |
Kainic Acid results in increased expression of GRIK2 mRNA [Celecoxib co-treated with Kainic Acid] results in decreased expression of GRIK2 mRNA |
CTD |
PMID:17997037 PMID:21589914 PMID:29208536 |
|
NCBI chr20:53,791,428...54,517,691
Ensembl chr20:53,789,760...54,517,709
|
|
G |
Grik3 |
glutamate ionotropic receptor kainate type subunit 3 |
decreases expression multiple interactions |
ISO |
Kainic Acid results in decreased expression of GRIK3 mRNA [Celecoxib co-treated with Kainic Acid] results in decreased expression of GRIK3 mRNA |
CTD |
PMID:21589914 |
|
NCBI chr 5:143,500,441...143,715,546
Ensembl chr 5:143,500,441...143,715,546
|
|
G |
Grik4 |
glutamate ionotropic receptor kainate type subunit 4 |
multiple interactions decreases expression |
ISO |
[Celecoxib co-treated with Kainic Acid] results in decreased expression of GRIK4 mRNA Kainic Acid results in decreased expression of GRIK4 mRNA |
CTD |
PMID:21589914 |
|
NCBI chr 8:46,804,134...47,237,546
Ensembl chr 8:46,806,147...47,094,352
|
|
G |
Grik5 |
glutamate ionotropic receptor kainate type subunit 5 |
multiple interactions decreases expression |
ISO |
Celecoxib promotes the reaction [Kainic Acid results in decreased expression of GRIK5 mRNA]; PTGS2 affects the reaction [Kainic Acid results in decreased expression of GRIK5 mRNA] |
CTD |
PMID:21589914 |
|
NCBI chr 1:81,885,516...81,946,731
Ensembl chr 1:81,885,521...81,946,714
|
|
G |
Grin1 |
glutamate ionotropic receptor NMDA type subunit 1 |
multiple interactions affects expression decreases expression |
ISO EXP |
celecoxib promotes the reaction [Kainic Acid results in decreased expression of GRIN1 mRNA] Kainic Acid affects the expression of GRIN1 |
CTD |
PMID:21589914 PMID:23159308 |
|
NCBI chr 3:2,507,745...2,534,664
Ensembl chr 3:2,506,896...2,534,663
|
|
G |
Grin2a |
glutamate ionotropic receptor NMDA type subunit 2A |
decreases expression multiple interactions |
ISO |
Kainic Acid results in decreased expression of GRIN2A mRNA celecoxib promotes the reaction [Kainic Acid results in decreased expression of GRIN2A mRNA] |
CTD |
PMID:21589914 |
|
NCBI chr10:5,707,806...6,123,568
Ensembl chr10:5,930,298...6,119,990
|
|
G |
Grin2b |
glutamate ionotropic receptor NMDA type subunit 2B |
multiple interactions decreases expression |
ISO |
celecoxib promotes the reaction [Kainic Acid results in decreased expression of GRIN2B mRNA] |
CTD |
PMID:21589914 |
|
NCBI chr 4:169,541,620...170,000,216
Ensembl chr 4:169,560,387...169,999,873
|
|
G |
Grin2c |
glutamate ionotropic receptor NMDA type subunit 2C |
decreases expression multiple interactions |
ISO |
Kainic Acid results in decreased expression of GRIN2C mRNA Celecoxib promotes the reaction [Kainic Acid results in decreased expression of GRIN2C mRNA]; PTGS2 affects the reaction [Kainic Acid results in decreased expression of GRIN2C mRNA] |
CTD |
PMID:21589914 |
|
NCBI chr10:103,798,290...103,816,923
Ensembl chr10:103,798,291...103,816,287
|
|
G |
Grin2d |
glutamate ionotropic receptor NMDA type subunit 2D |
decreases expression multiple interactions |
ISO |
Kainic Acid results in decreased expression of GRIN2D mRNA Celecoxib promotes the reaction [Kainic Acid results in decreased expression of GRIN2D mRNA]; PTGS2 affects the reaction [Kainic Acid results in decreased expression of GRIN2D mRNA] |
CTD |
PMID:21589914 |
|
NCBI chr 1:101,819,068...101,859,146
Ensembl chr 1:101,820,461...101,856,881
|
|
G |
Grin3a |
glutamate ionotropic receptor NMDA type subunit 3A |
multiple interactions decreases expression |
ISO |
Celecoxib promotes the reaction [Kainic Acid results in decreased expression of GRIN3A mRNA]; PTGS2 affects the reaction [Kainic Acid results in decreased expression of GRIN3A mRNA] |
CTD |
PMID:21589914 |
|
NCBI chr 5:64,928,620...65,073,012
Ensembl chr 5:64,928,620...65,073,012
|
|
G |
Grin3b |
glutamate ionotropic receptor NMDA type subunit 3B |
decreases expression multiple interactions |
ISO |
Kainic Acid results in decreased expression of GRIN3B mRNA celecoxib promotes the reaction [Kainic Acid results in decreased expression of GRIN3B mRNA] |
CTD |
PMID:21589914 |
|
NCBI chr 7:12,764,993...12,771,310
Ensembl chr 7:12,764,993...12,771,310
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
decreases activity decreases phosphorylation multiple interactions |
ISO |
Kainic Acid results in decreased activity of GSK3B protein Kainic Acid results in decreased phosphorylation of GSK3B protein 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione inhibits the reaction [Kainic Acid results in decreased phosphorylation of GSK3B protein]; 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione promotes the reaction [Valproic Acid inhibits the reaction [Kainic Acid results in decreased phosphorylation of GSK3B protein]]; Valproic Acid inhibits the reaction [Kainic Acid results in decreased phosphorylation of GSK3B protein] |
CTD |
PMID:18619545 PMID:25453207 |
|
NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions decreases activity |
EXP |
oridonin inhibits the reaction [Kainic Acid results in decreased activity of GSR protein] |
CTD |
PMID:31430510 |
|
NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
|
|
G |
Hcn1 |
hyperpolarization-activated cyclic nucleotide-gated potassium channel 1 |
multiple interactions decreases expression |
EXP |
Kainic Acid promotes the reaction [REST protein binds to HCN1 intron]; REST mutant form inhibits the reaction [Kainic Acid promotes the reaction [REST protein binds to HCN1 intron]]; REST mutant form inhibits the reaction [Kainic Acid results in decreased expression of HCN1 mRNA]; REST mutant form inhibits the reaction [Kainic Acid results in decreased expression of HCN1 protein] Kainic Acid results in decreased expression of HCN1 mRNA; Kainic Acid results in decreased expression of HCN1 protein |
CTD |
PMID:21905079 |
|
NCBI chr 2:50,099,576...50,499,799
Ensembl chr 2:50,099,576...50,499,799
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
EXP |
Kainic Acid results in increased expression of HMOX1 mRNA |
CTD |
PMID:7655348 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Homer1 |
homer scaffold protein 1 |
increases expression |
EXP |
Kainic Acid results in increased expression of HOMER1 mRNA |
CTD |
PMID:19700661 |
|
NCBI chr 2:22,909,550...23,012,303
Ensembl chr 2:22,909,569...23,009,678
|
|
G |
Hpca |
hippocalcin |
decreases response to substance |
ISO |
HPCA protein results in decreased susceptibility to Kainic Acid |
CTD |
PMID:15607944 |
|
NCBI chr 5:147,295,124...147,305,757
Ensembl chr 5:147,294,820...147,303,346
|
|
G |
Hsd11b1 |
hydroxysteroid 11-beta dehydrogenase 1 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of HSD11B1 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr13:111,946,626...111,996,536
Ensembl chr13:111,926,442...111,972,603
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
multiple interactions |
ISO |
[Kainic Acid co-treated with dihydroxyethyldithiocarbamate] results in increased expression of HSPA1A protein; Dizocilpine Maleate inhibits the reaction [[Kainic Acid co-treated with dihydroxyethyldithiocarbamate] results in increased expression of HSPA1A protein]; GYKI 52466 inhibits the reaction [[Kainic Acid co-treated with dihydroxyethyldithiocarbamate] results in increased expression of HSPA1A protein] |
CTD |
PMID:16686654 |
|
NCBI chr20:4,875,834...4,881,751
Ensembl chr20:4,877,324...4,879,779
|
|
G |
Idi1 |
isopentenyl-diphosphate delta isomerase 1 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of IDI1 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr17:57,976,266...57,984,036
Ensembl chr17:57,976,268...57,984,036
|
|
G |
Il10 |
interleukin 10 |
decreases expression |
EXP |
Kainic Acid results in decreased expression of IL10 protein |
CTD |
PMID:15591643 |
|
NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
|
|
G |
Il12a |
interleukin 12A |
affects response to substance |
ISO |
IL12A protein affects the susceptibility to Kainic Acid |
CTD |
PMID:15474355 |
|
NCBI chr 2:165,076,945...165,083,996
Ensembl chr 2:165,076,607...165,084,318
|
|
G |
Il1b |
interleukin 1 beta |
increases secretion increases expression multiple interactions |
EXP ISO |
Kainic Acid results in increased secretion of IL1B protein Kainic Acid results in increased expression of IL1B mRNA; Kainic Acid results in increased expression of IL1B protein PTGS2 affects the reaction [Kainic Acid results in increased expression of IL1B mRNA] Minocycline inhibits the reaction [Kainic Acid results in increased secretion of IL1B protein]; oridonin inhibits the reaction [Kainic Acid results in increased expression of IL1B protein] |
CTD |
PMID:7655348 PMID:11306611 PMID:21589914 PMID:31430510 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6 |
interleukin 6 |
increases response to substance multiple interactions increases expression |
ISO EXP |
IL6 protein results in increased susceptibility to Kainic Acid oridonin inhibits the reaction [Kainic Acid results in increased expression of IL6 protein] Kainic Acid results in increased expression of IL6 mRNA PTGS2 affects the reaction [Kainic Acid results in increased expression of IL6 mRNA] |
CTD |
PMID:12836160 PMID:21589914 PMID:31430510 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Itgam |
integrin subunit alpha M |
increases expression multiple interactions |
ISO |
Kainic Acid results in increased expression of ITGAM mRNA PTGS2 affects the reaction [Kainic Acid results in increased expression of ITGAM mRNA] |
CTD |
PMID:21589914 |
|
NCBI chr 1:199,495,312...199,545,738
Ensembl chr 1:199,495,298...199,623,960
|
|
G |
Jagn1 |
jagunal homolog 1 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of JAGN1 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 4:145,399,885...145,404,605
Ensembl chr 4:145,399,913...145,404,617
|
|
G |
Jak2 |
Janus kinase 2 |
multiple interactions decreases expression |
ISO EXP |
EPO protein inhibits the reaction [Kainic Acid results in decreased expression of JAK2 protein]; EPOR protein promotes the reaction [EPO protein inhibits the reaction [Kainic Acid results in decreased expression of JAK2 protein]] |
CTD |
PMID:18711747 |
|
NCBI chr 1:247,398,667...247,457,521
Ensembl chr 1:247,398,598...247,458,509
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
EXP |
[Curcumin co-treated with Manganese] inhibits the reaction [Kainic Acid results in increased expression of JUN mRNA]; [diacetylcurcumin co-treated with Manganese] inhibits the reaction [Kainic Acid results in increased expression of JUN mRNA]; Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of JUN mRNA]; Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of JUN protein]; Diazepam inhibits the reaction [Kainic Acid results in increased expression of JUN protein]; dimemorfan inhibits the reaction [Kainic Acid results in increased expression of JUN mRNA]; dimemorfan inhibits the reaction [Kainic Acid results in increased expression of JUN protein]; N-(2-(3,4-Dichlorphenyl)ethyl)-N,N',N'-trimethyl-1,2-ethandiamin inhibits the reaction [Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of JUN mRNA]]; N-(2-(3,4-Dichlorphenyl)ethyl)-N,N',N'-trimethyl-1,2-ethandiamin inhibits the reaction [Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of JUN protein]]; N-(2-(3,4-Dichlorphenyl)ethyl)-N,N',N'-trimethyl-1,2-ethandiamin inhibits the reaction [dimemorfan inhibits the reaction [Kainic Acid results in increased expression of JUN mRNA]]; N-(2-(3,4-Dichlorphenyl)ethyl)-N,N',N'-trimethyl-1,2-ethandiamin inhibits the reaction [dimemorfan inhibits the reaction [Kainic Acid results in increased expression of JUN protein]]; Pentobarbital inhibits the reaction [Kainic Acid results in increased expression of JUN protein]; SIGMAR1 protein affects the reaction [Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of JUN mRNA]]; SIGMAR1 protein affects the reaction [Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of JUN protein]]; SIGMAR1 protein affects the reaction [dimemorfan inhibits the reaction [Kainic Acid results in increased expression of JUN mRNA]]; SIGMAR1 protein affects the reaction [dimemorfan inhibits the reaction [Kainic Acid results in increased expression of JUN protein]]; Valproic Acid inhibits the reaction [Kainic Acid results in increased expression of JUN protein] Kainic Acid results in increased expression of JUN mRNA; Kainic Acid results in increased expression of JUN protein |
CTD |
PMID:8417141 PMID:15723099 PMID:17827730 |
|
NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
|
|
G |
Junb |
JunB proto-oncogene, AP-1 transcription factor subunit |
decreases expression increases expression |
ISO EXP |
Kainic Acid results in decreased expression of JUNB mRNA Kainic Acid results in increased expression of JUNB mRNA |
CTD |
PMID:17997037 PMID:19700661 |
|
NCBI chr19:26,092,972...26,094,756
Ensembl chr19:26,092,974...26,094,756
|
|
G |
Kalrn |
kalirin, RhoGEF kinase |
increases expression |
EXP |
Kainic Acid results in increased expression of KALRN mRNA |
CTD |
PMID:19700661 |
|
NCBI chr11:69,484,293...70,025,682
Ensembl chr11:69,484,293...70,025,633
|
|
G |
Kcnc2 |
potassium voltage-gated channel subfamily C member 2 |
increases expression |
EXP |
Kainic Acid results in increased expression of KCNC2 protein |
CTD |
PMID:7643197 |
|
NCBI chr 7:54,978,453...55,159,362
Ensembl chr 7:54,980,120...55,159,351
|
|
G |
Kcnc4 |
potassium voltage-gated channel subfamily C member 4 |
decreases expression |
EXP |
Kainic Acid results in decreased expression of KCNC4 protein |
CTD |
PMID:21905079 |
|
NCBI chr 2:210,220,908...210,241,447
Ensembl chr 2:210,220,908...210,241,455
|
|
G |
Kcnq2 |
potassium voltage-gated channel subfamily Q member 2 |
increases response to substance |
ISO |
KCNQ2 protein mutant form results in increased susceptibility to Kainic Acid |
CTD |
PMID:26910900 |
|
NCBI chr 3:176,585,897...176,645,029
Ensembl chr 3:176,589,906...176,644,951
|
|
G |
Kif20a |
kinesin family member 20A |
decreases expression |
ISO |
Kainic Acid results in decreased expression of KIF20A mRNA |
CTD |
PMID:17997037 |
|
NCBI chr18:27,424,328...27,432,814
Ensembl chr18:27,424,328...27,432,814
|
|
G |
Klf10 |
Kruppel-like factor 10 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of KLF10 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 7:77,156,010...77,162,096
Ensembl chr 7:77,156,006...77,162,148
|
|
G |
Kng2 |
kininogen 2 |
multiple interactions |
EXP |
Kainic Acid promotes the reaction [Nicotine results in decreased activity of KNG1 protein alternative form] |
CTD |
PMID:7807204 |
|
NCBI chr11:81,509,185...81,516,759
|
|
G |
Kras |
KRAS proto-oncogene, GTPase |
increases expression |
EXP |
Kainic Acid results in increased expression of KRAS mRNA |
CTD |
PMID:19700661 |
|
NCBI chr 4:179,482,562...179,515,483
Ensembl chr 4:179,486,105...179,515,558
|
|
G |
Lep |
leptin |
decreases response to substance |
ISO |
LEP protein results in decreased susceptibility to Kainic Acid |
CTD |
PMID:17993459 |
|
NCBI chr 4:56,337,695...56,351,818
Ensembl chr 4:56,337,695...56,351,818
|
|
G |
Lmo1 |
LIM domain only 1 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of LMO1 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 1:173,728,183...173,764,288
Ensembl chr 1:173,728,184...173,764,250
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions increases expression |
EXP |
NADP inhibits the reaction [Kainic Acid results in increased expression of MAP1LC3B protein modified form] |
CTD |
PMID:32057834 |
|
NCBI chr19:53,635,449...53,643,970
Ensembl chr19:53,629,779...53,646,058
|
|
G |
Map2 |
microtubule-associated protein 2 |
multiple interactions increases expression |
ISO |
PTGS2 affects the reaction [Kainic Acid results in increased expression of MAP2 mRNA] |
CTD |
PMID:21589914 |
|
NCBI chr 9:73,204,753...73,462,965
Ensembl chr 9:73,319,710...73,462,972
|
|
G |
Map3k5 |
mitogen-activated protein kinase kinase kinase 5 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of MAP3K5 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 1:15,412,603...15,613,752
Ensembl chr 1:15,412,603...15,613,746
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases expression |
ISO |
Kainic Acid results in increased expression of MAPK3 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mast3 |
microtubule associated serine/threonine kinase 3 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of MAST3 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr16:20,387,330...20,414,767
Ensembl chr16:20,395,845...20,414,767
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases activity multiple interactions |
ISO |
Kainic Acid results in increased activity of MMP9 protein MMP9 protein affects the reaction [Kainic Acid results in decreased expression of NCAM1 protein modified form] |
CTD |
PMID:30772382 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Mpdz |
multiple PDZ domain crumbs cell polarity complex component |
affects response to substance |
ISO |
MPDZ protein affects the susceptibility to Kainic Acid |
CTD |
PMID:14960011 |
|
NCBI chr 5:99,413,184...99,566,356
Ensembl chr 5:99,413,187...99,566,318
|
|
G |
Mpeg1 |
macrophage expressed 1 |
increases expression |
ISO |
Kainic Acid results in increased expression of MPEG1 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 1:228,724,559...228,729,054
Ensembl chr 1:228,724,900...228,727,160
|
|
G |
Msmo1 |
methylsterol monooxygenase 1 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of MSMO1 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr16:26,859,441...26,875,880
Ensembl chr16:26,859,397...26,875,973
|
|
G |
Mt1 |
metallothionein 1 |
decreases response to substance increases expression |
ISO EXP |
MT1 protein results in decreased susceptibility to Kainic Acid Kainic Acid results in increased expression of MT1A mRNA |
CTD |
PMID:7655348 PMID:10947810 |
|
NCBI chr19:11,301,991...11,303,007
Ensembl chr17:78,793,336...78,793,724
|
|
G |
Mt2A |
metallothionein 2A |
decreases response to substance |
ISO |
MT2 protein results in decreased susceptibility to Kainic Acid |
CTD |
PMID:10947810 |
|
NCBI chr19:11,307,966...11,308,740
Ensembl chr19:11,307,967...11,308,740
|
|
G |
Myo5b |
myosin Vb |
decreases expression |
ISO |
Kainic Acid results in decreased expression of MYO5B mRNA |
CTD |
PMID:17997037 |
|
NCBI chr18:70,426,865...70,729,985
Ensembl chr18:70,427,007...70,729,030
|
|
G |
Myo9a |
myosin IXA |
increases expression |
ISO |
Kainic Acid results in increased expression of MYO9A mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 8:64,573,248...64,777,607
Ensembl chr 8:64,573,358...64,777,543
|
|
G |
Naip6 |
NLR family, apoptosis inhibitory protein 6 |
increases expression |
EXP ISO |
Kainic Acid results in increased expression of NAIP mRNA; Kainic Acid results in increased expression of NAIP protein |
CTD |
PMID:12547647 PMID:15046874 |
|
NCBI chr 2:30,377,505...30,418,578
|
|
G |
Ncam1 |
neural cell adhesion molecule 1 |
decreases expression multiple interactions |
EXP ISO |
Kainic Acid results in decreased expression of NCAM1 mRNA MMP9 protein affects the reaction [Kainic Acid results in decreased expression of NCAM1 protein modified form] |
CTD |
PMID:19700661 PMID:30772382 |
|
NCBI chr 8:53,836,797...54,134,881
Ensembl chr 8:53,839,098...53,901,358
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
affects localization |
ISO |
Kainic Acid affects the localization of NFE2L2 protein |
CTD |
PMID:18619545 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nos1 |
nitric oxide synthase 1 |
multiple interactions increases expression decreases expression |
EXP |
2-(2-(4-(4-nitrobenzyloxy)phenyl)ethyl)isothiourea methanesulfonate inhibits the reaction [Kainic Acid results in decreased expression of NOS1 protein] Kainic Acid results in increased expression of NOS1 mRNA; Kainic Acid results in increased expression of NOS1 protein |
CTD |
PMID:17585341 PMID:18375135 |
|
NCBI chr12:44,214,949...44,405,530
Ensembl chr12:44,213,943...44,520,341
|
|
G |
Nos2 |
nitric oxide synthase 2 |
increases expression multiple interactions |
ISO EXP |
Kainic Acid results in increased expression of NOS2 mRNA Kainic Acid results in increased expression of NOS2 mRNA; Kainic Acid results in increased expression of NOS2 protein PTGS2 affects the reaction [Kainic Acid results in increased expression of NOS2 mRNA] [Curcumin co-treated with Manganese] inhibits the reaction [Kainic Acid results in increased expression of NOS2 mRNA]; [diacetylcurcumin co-treated with Manganese] inhibits the reaction [Kainic Acid results in increased expression of NOS2 mRNA]; Curcumin inhibits the reaction [Kainic Acid results in increased expression of NOS2 mRNA] |
CTD |
PMID:17827730 PMID:18375135 PMID:21589914 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Npy |
neuropeptide Y |
decreases response to substance multiple interactions increases expression |
ISO EXP |
NPY protein results in decreased susceptibility to Kainic Acid Thiopental inhibits the reaction [Kainic Acid results in increased expression of NPY mRNA] |
CTD |
PMID:9427505 PMID:15451008 |
|
NCBI chr 4:79,557,856...79,565,059
Ensembl chr 4:79,557,854...79,565,097
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
decreases expression increases expression |
ISO EXP |
Kainic Acid results in decreased expression of NR4A1 mRNA Kainic Acid results in increased expression of NR4A1 mRNA |
CTD |
PMID:17997037 PMID:19700661 |
|
NCBI chr 7:142,899,358...142,920,216
Ensembl chr 7:142,905,758...142,920,216
|
|
G |
Nr4a2 |
nuclear receptor subfamily 4, group A, member 2 |
increases expression |
EXP ISO |
Kainic Acid results in increased expression of NR4A2 mRNA Kainic Acid results in increased expression of NR4A2 protein |
CTD |
PMID:19700661 PMID:24813937 |
|
NCBI chr 3:43,111,258...43,128,391
Ensembl chr 3:43,111,240...43,119,159
|
|
G |
Nr4a3 |
nuclear receptor subfamily 4, group A, member 3 |
increases expression |
EXP |
Kainic Acid results in increased expression of NR4A3 mRNA |
CTD |
PMID:19700661 |
|
NCBI chr 5:63,781,801...63,822,890
Ensembl chr 5:63,781,801...63,821,637
|
|
G |
Nrp2 |
neuropilin 2 |
affects response to substance |
ISO |
NRP2 protein affects the susceptibility to Kainic Acid |
CTD |
PMID:18657176 |
|
NCBI chr 9:69,496,875...69,609,802
Ensembl chr 9:69,497,121...69,612,087
|
|
G |
Ntn1 |
netrin 1 |
increases expression |
EXP |
Kainic Acid results in increased expression of NTN1 mRNA |
CTD |
PMID:19700661 |
|
NCBI chr10:54,761,925...54,982,072
Ensembl chr10:54,761,871...54,967,585
|
|
G |
Ntrk2 |
neurotrophic receptor tyrosine kinase 2 |
increases expression |
EXP |
Kainic Acid results in increased expression of NTRK2 mRNA |
CTD |
PMID:19700661 |
|
NCBI chr17:5,934,651...6,245,778
Ensembl chr17:5,933,729...6,244,676
|
|
G |
Nudcd2 |
NudC domain containing 2 |
increases expression |
ISO |
Kainic Acid results in increased expression of NUDCD2 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr10:25,890,943...25,896,432
Ensembl chr10:25,890,943...25,896,432
|
|
G |
Nudt4 |
nudix hydrolase 4 |
increases expression |
ISO |
Kainic Acid results in increased expression of NUDT4 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 7:36,643,916...36,660,334
Ensembl chr 7:36,643,916...36,660,141
|
|
G |
Otx2 |
orthodenticle homeobox 2 |
decreases expression |
EXP |
Kainic Acid results in decreased expression of OTX2 mRNA |
CTD |
PMID:19700661 |
|
NCBI chr15:25,500,037...25,511,619
Ensembl chr15:25,502,019...25,505,691
|
|
G |
Pak3 |
p21 (RAC1) activated kinase 3 |
decreases expression |
EXP |
Kainic Acid results in decreased expression of PAK3 mRNA |
CTD |
PMID:19700661 |
|
NCBI chr X:114,784,452...115,042,683
Ensembl chr X:114,929,029...115,036,669
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases activity |
EXP |
Kainic Acid results in increased activity of PARP1 protein |
CTD |
PMID:28704930 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Pdyn |
prodynorphin |
multiple interactions increases expression |
EXP |
Diazepam inhibits the reaction [Kainic Acid results in increased expression of PDYN mRNA]; Pentobarbital inhibits the reaction [Kainic Acid results in increased expression of PDYN mRNA]; Valproic Acid inhibits the reaction [Kainic Acid results in increased expression of PDYN mRNA] |
CTD |
PMID:8417141 |
|
NCBI chr 3:122,194,327...122,206,671
Ensembl chr 3:122,194,329...122,206,671
|
|
G |
Penk |
proenkephalin |
multiple interactions increases expression |
EXP |
Diazepam inhibits the reaction [Kainic Acid results in increased expression of PENK mRNA]; Pentobarbital inhibits the reaction [Kainic Acid results in increased expression of PENK mRNA]; Thiopental inhibits the reaction [Kainic Acid results in increased expression of PENK mRNA]; Valproic Acid inhibits the reaction [Kainic Acid results in increased expression of PENK mRNA] |
CTD |
PMID:8417141 PMID:9427505 |
|
NCBI chr 5:17,056,412...17,061,762
Ensembl chr 5:17,056,419...17,061,837
|
|
G |
Pick1 |
protein interacting with PRKCA 1 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of PICK1 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 7:120,465,472...120,484,824
Ensembl chr 7:120,465,130...120,484,840
|
|
G |
Pkp2 |
plakophilin 2 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of PKP2 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr11:88,912,163...88,972,213
|
|
G |
Plod3 |
procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of PLOD3 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr12:22,716,421...22,726,982
Ensembl chr12:22,716,423...22,726,982
|
|
G |
Ppif |
peptidylprolyl isomerase F |
increases response to substance |
ISO |
PPIF results in increased susceptibility to Kainic Acid |
CTD |
PMID:21378209 |
|
NCBI chr16:1,979,191...1,985,912
Ensembl chr16:1,979,191...1,985,908
|
|
G |
Ppp1r9b |
protein phosphatase 1, regulatory subunit 9B |
increases expression |
EXP |
Kainic Acid results in increased expression of PPP1R9B protein |
CTD |
PMID:17443789 |
|
NCBI chr10:82,800,704...82,816,735
Ensembl chr10:82,800,704...82,816,731
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases response to substance increases expression |
EXP ISO |
[Curcumin co-treated with Manganese] inhibits the reaction [Kainic Acid results in increased expression of PTGS2 mRNA]; [diacetylcurcumin co-treated with Manganese] inhibits the reaction [Kainic Acid results in increased expression of PTGS2 mRNA]; oridonin inhibits the reaction [Kainic Acid results in increased expression of PTGS2 protein] [PTGS2 gene mutant form results in increased susceptibility to Kainic Acid] which results in increased abundance of Dinoprost; [PTGS2 gene mutant form results in increased susceptibility to Kainic Acid] which results in increased abundance of Dinoprostone; [PTGS2 gene mutant form results in increased susceptibility to Kainic Acid] which results in increased abundance of Prostaglandin D2; [PTGS2 gene mutant form results in increased susceptibility to Kainic Acid] which results in increased abundance of Thromboxane B2; PTGS2 affects the reaction [Kainic Acid results in decreased expression of GRIA1 mRNA]; PTGS2 affects the reaction [Kainic Acid results in decreased expression of GRIK1 mRNA]; PTGS2 affects the reaction [Kainic Acid results in decreased expression of GRIK5 mRNA]; PTGS2 affects the reaction [Kainic Acid results in decreased expression of GRIN2C mRNA]; PTGS2 affects the reaction [Kainic Acid results in decreased expression of GRIN2D mRNA]; PTGS2 affects the reaction [Kainic Acid results in decreased expression of GRIN3A mRNA]; PTGS2 affects the reaction [Kainic Acid results in increased expression of GFAP mRNA]; PTGS2 affects the reaction [Kainic Acid results in increased expression of IL1B mRNA]; PTGS2 affects the reaction [Kainic Acid results in increased expression of IL6 mRNA]; PTGS2 affects the reaction [Kainic Acid results in increased expression of ITGAM mRNA]; PTGS2 affects the reaction [Kainic Acid results in increased expression of MAP2 mRNA]; PTGS2 affects the reaction [Kainic Acid results in increased expression of NOS2 mRNA]; PTGS2 affects the reaction [Kainic Acid results in increased expression of RELA mRNA]; PTGS2 affects the reaction [Kainic Acid results in increased expression of TNF mRNA] Kainic Acid results in increased expression of PTGS2; Kainic Acid results in increased expression of PTGS2 mRNA; Kainic Acid results in increased expression of PTGS2 protein |
CTD |
PMID:11168565 PMID:12618123 PMID:17827730 PMID:18834901 PMID:19700661 PMID:21589914 PMID:31430510 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Qk |
quaking |
increases expression |
ISO |
Kainic Acid results in increased expression of QK mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 1:50,983,647...51,050,692
|
|
G |
Rac1 |
Rac family small GTPase 1 |
increases expression |
EXP |
Kainic Acid results in increased expression of RAC1 mRNA |
CTD |
PMID:19700661 |
|
NCBI chr12:13,090,316...13,111,841
Ensembl chr12:13,090,172...13,111,873
|
|
G |
Rad23a |
RAD23 homolog A, nucleotide excision repair protein |
increases expression |
EXP |
Kainic Acid results in increased expression of RAD23A mRNA |
CTD |
PMID:19700661 |
|
NCBI chr19:25,949,488...25,956,677
Ensembl chr19:25,949,490...25,955,391
|
|
G |
Rasd1 |
ras related dexamethasone induced 1 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of RASD1 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr10:46,330,361...46,339,326
Ensembl chr10:46,330,368...46,332,172
|
|
G |
Rbfox1 |
RNA binding fox-1 homolog 1 |
increases response to substance |
ISO |
RBFOX1 gene mutant form results in increased susceptibility to Kainic Acid |
CTD |
PMID:21623373 |
|
NCBI chr10:8,312,961...10,437,778
Ensembl chr10:8,312,961...8,654,892
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions increases expression |
ISO |
PTGS2 affects the reaction [Kainic Acid results in increased expression of RELA mRNA] |
CTD |
PMID:21589914 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Rest |
RE1-silencing transcription factor |
increases expression multiple interactions |
EXP |
Kainic Acid results in increased expression of REST protein Kainic Acid promotes the reaction [REST protein binds to HCN1 intron]; REST mutant form inhibits the reaction [Kainic Acid promotes the reaction [REST protein binds to HCN1 intron]]; REST mutant form inhibits the reaction [Kainic Acid results in decreased expression of HCN1 mRNA]; REST mutant form inhibits the reaction [Kainic Acid results in decreased expression of HCN1 protein] |
CTD |
PMID:21905079 |
|
NCBI chr14:33,131,985...33,152,019
Ensembl chr14:33,134,511...33,164,141
|
|
G |
Rgs16 |
regulator of G-protein signaling 16 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of RGS16 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr13:71,163,411...71,185,147
Ensembl chr13:71,179,910...71,185,216
|
|
G |
Rhoa |
ras homolog family member A |
increases expression |
EXP |
Kainic Acid results in increased expression of RHOA mRNA |
CTD |
PMID:19700661 |
|
NCBI chr 8:117,082,440...117,116,244
Ensembl chr 8:117,106,576...117,116,167
|
|
G |
S1pr1 |
sphingosine-1-phosphate receptor 1 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of S1PR1 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 2:218,654,406...218,658,761
Ensembl chr 2:218,654,554...218,658,761
|
|
G |
Sap30l |
SAP30-like |
decreases expression |
ISO |
Kainic Acid results in decreased expression of SAP30L mRNA |
CTD |
PMID:17997037 |
|
NCBI chr10:43,224,151...43,231,864
Ensembl chr10:43,224,269...43,231,611
|
|
G |
Sema4d |
semaphorin 4D |
increases expression |
EXP |
Kainic Acid results in increased expression of SEMA4D mRNA |
CTD |
PMID:19700661 |
|
NCBI chr17:13,516,276...13,538,513
Ensembl chr17:13,488,376...13,553,974
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions increases expression |
ISO |
Guanethidine inhibits the reaction [Kainic Acid results in increased expression of SERPINE1 mRNA]; Mecamylamine inhibits the reaction [Kainic Acid results in increased expression of SERPINE1 mRNA]; Phentolamine inhibits the reaction [Kainic Acid results in increased expression of SERPINE1 mRNA] |
CTD |
PMID:15850565 |
|
NCBI chr12:22,641,104...22,651,482
Ensembl chr12:22,641,104...22,651,482
|
|
G |
Sfpq |
splicing factor proline and glutamine rich |
increases expression |
ISO |
Kainic Acid results in increased expression of SFPQ mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 5:145,079,803...145,088,517
Ensembl chr 5:145,079,803...145,088,498
|
|
G |
Sigmar1 |
sigma non-opioid intracellular receptor 1 |
multiple interactions |
EXP |
SIGMAR1 protein affects the reaction [Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of FOS mRNA]]; SIGMAR1 protein affects the reaction [Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of FOS protein]]; SIGMAR1 protein affects the reaction [Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of JUN mRNA]]; SIGMAR1 protein affects the reaction [Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of JUN protein]]; SIGMAR1 protein affects the reaction [dimemorfan inhibits the reaction [Kainic Acid results in increased expression of FOS mRNA]]; SIGMAR1 protein affects the reaction [dimemorfan inhibits the reaction [Kainic Acid results in increased expression of FOS protein]]; SIGMAR1 protein affects the reaction [dimemorfan inhibits the reaction [Kainic Acid results in increased expression of JUN mRNA]]; SIGMAR1 protein affects the reaction [dimemorfan inhibits the reaction [Kainic Acid results in increased expression of JUN protein]] |
CTD |
PMID:15723099 |
|
NCBI chr 5:58,121,824...58,124,687
Ensembl chr 5:58,121,786...58,124,681
|
|
G |
Sirt1 |
sirtuin 1 |
decreases expression increases expression |
ISO EXP |
Kainic Acid results in decreased expression of SIRT1 protein Kainic Acid results in increased expression of SIRT1 protein |
CTD |
PMID:18538940 |
|
NCBI chr20:26,831,971...26,851,587
Ensembl chr20:26,833,357...26,852,199
|
|
G |
Slc11a2 |
solute carrier family 11 member 2 |
increases expression |
EXP |
Kainic Acid results in increased expression of SLC11A2 |
CTD |
PMID:16552559 |
|
NCBI chr 7:142,025,812...142,062,892
Ensembl chr 7:142,025,815...142,063,212
|
|
G |
Slc1a1 |
solute carrier family 1 member 1 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of SLC1A1 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 1:246,955,017...247,035,159
Ensembl chr 1:246,954,980...247,037,056
|
|
G |
Slc1a2 |
solute carrier family 1 member 2 |
multiple interactions increases expression |
ISO EXP |
[Kainic Acid co-treated with zinc chloride] results in decreased expression of SLC1A2 protein Ceftriaxone promotes the reaction [Kainic Acid results in increased expression of SLC1A2 protein] |
CTD |
PMID:19061913 PMID:28257918 |
|
NCBI chr 3:92,518,679...92,665,731
Ensembl chr 3:92,640,752...92,665,644
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Kainic Acid inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,318,025...48,360,219
Ensembl chr 1:48,317,995...48,360,261
|
|
G |
Slc6a2 |
solute carrier family 6 member 2 |
increases response to substance |
ISO |
SLC6A2 protein results in increased susceptibility to Kainic Acid |
CTD |
PMID:15911120 |
|
NCBI chr19:15,391,682...15,431,274
Ensembl chr19:15,391,581...15,431,274
|
|
G |
Slc8a3 |
solute carrier family 8 member A3 |
multiple interactions increases expression increases cleavage |
EXP |
2-(2-(4-(4-nitrobenzyloxy)phenyl)ethyl)isothiourea methanesulfonate inhibits the reaction [Kainic Acid results in increased cleavage of SLC8A3 protein] Kainic Acid results in increased expression of SLC8A3 protein |
CTD |
PMID:17585341 PMID:20928830 |
|
NCBI chr 6:104,889,500...105,099,408
Ensembl chr 6:104,891,376...105,097,054
|
|
G |
Snrk |
SNF related kinase |
decreases expression |
ISO |
Kainic Acid results in decreased expression of SNRK mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 8:130,749,806...130,805,225
Ensembl chr 8:130,749,838...130,803,597
|
|
G |
Sod1 |
superoxide dismutase 1 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of SOD1 protein |
CTD |
PMID:29208536 |
|
NCBI chr11:30,363,282...30,368,858
Ensembl chr11:30,363,280...30,368,862
|
|
G |
Sod2 |
superoxide dismutase 2 |
decreases expression increases expression |
EXP ISO |
Kainic Acid results in decreased expression of SOD2 protein Kainic Acid results in decreased expression of SOD2 mRNA; Kainic Acid results in decreased expression of SOD2 protein Kainic Acid results in increased expression of SOD2 protein |
CTD |
PMID:10686417 PMID:29208536 |
|
NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
|
|
G |
Sptan1 |
spectrin, alpha, non-erythrocytic 1 |
increases expression |
EXP |
Kainic Acid results in increased expression of SPTAN1 protein modified form |
CTD |
PMID:22790971 |
|
NCBI chr 3:8,534,437...8,599,259
Ensembl chr 3:8,534,440...8,599,260
|
|
G |
Sqstm1 |
sequestosome 1 |
decreases expression multiple interactions |
EXP |
Kainic Acid results in decreased expression of SQSTM1 protein NADP inhibits the reaction [Kainic Acid results in decreased expression of SQSTM1 protein] |
CTD |
PMID:32057834 |
|
NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
|
|
G |
Sst |
somatostatin |
decreases expression |
ISO |
Kainic Acid results in decreased expression of SST mRNA |
CTD |
PMID:17997037 |
|
NCBI chr11:80,358,172...80,359,449
Ensembl chr11:80,358,211...80,359,444
|
|
G |
Tac1 |
tachykinin, precursor 1 |
decreases expression |
EXP |
Kainic Acid results in decreased expression of TAC1 protein |
CTD |
PMID:6205719 |
|
NCBI chr 4:33,638,853...33,646,819
Ensembl chr 4:33,638,709...33,646,819
|
|
G |
Tigar |
TP53 induced glycolysis regulatory phosphatase |
decreases expression multiple interactions |
EXP |
Kainic Acid results in decreased expression of TIGAR protein NADP inhibits the reaction [Kainic Acid results in decreased expression of TIGAR protein] |
CTD |
PMID:32057834 |
|
NCBI chr 4:159,635,145...159,654,108
Ensembl chr 4:159,635,153...159,654,063
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression |
ISO EXP |
PTGS2 affects the reaction [Kainic Acid results in increased expression of TNF mRNA]; TNF protein promotes the reaction [Kainic Acid results in increased uptake of Cobalt] oridonin inhibits the reaction [Kainic Acid results in increased expression of TNF protein] Kainic Acid results in increased expression of TNF mRNA; Kainic Acid results in increased expression of TNF protein |
CTD |
PMID:15869941 PMID:19700661 PMID:21589914 PMID:31430510 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tp53 |
tumor protein p53 |
increases expression |
EXP |
Kainic Acid results in increased expression of TP53 protein |
CTD |
PMID:20955365 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Trh |
thyrotropin releasing hormone |
decreases expression increases expression |
EXP |
Kainic Acid results in decreased expression of TRH mRNA Kainic Acid results in increased expression of TRH mRNA |
CTD |
PMID:10443546 |
|
NCBI chr 4:124,110,716...124,113,242
Ensembl chr 4:124,110,716...124,113,242
|
|
G |
Trhr |
thyrotropin releasing hormone receptor |
decreases expression |
EXP |
Kainic Acid results in decreased expression of TRHR protein |
CTD |
PMID:10443546 |
|
NCBI chr 7:83,113,641...83,153,520
Ensembl chr 7:83,113,672...83,153,519
|
|
G |
Tyrobp |
transmembrane immune signaling adaptor Tyrobp |
increases expression |
ISO |
Kainic Acid results in increased expression of TYROBP mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 1:88,875,370...88,879,305
Ensembl chr 1:88,875,375...88,879,303
|
|
G |
Uchl1 |
ubiquitin C-terminal hydrolase L1 |
increases expression |
EXP |
Kainic Acid results in increased expression of UCHL1 protein |
CTD |
PMID:22790971 |
|
NCBI chr14:43,133,224...43,143,942
Ensembl chr14:43,133,218...43,143,973
|
|
G |
Uhmk1 |
U2AF homology motif kinase 1 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of UHMK1 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr13:88,521,625...88,536,728
Ensembl chr13:88,521,625...88,536,728
|
|
G |
Uri1 |
URI1, prefoldin-like chaperone |
increases expression |
ISO |
Kainic Acid results in increased expression of URI1 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 1:94,346,513...94,404,362
Ensembl chr 1:94,346,514...94,404,211
|
|
G |
Utp3 |
UTP3, small subunit processome component |
decreases expression |
ISO |
Kainic Acid results in decreased expression of UTP3 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr14:21,153,998...21,155,652
Ensembl chr14:21,154,000...21,155,652
|
|
G |
Vamp7 |
vesicle-associated membrane protein 7 |
decreases expression |
EXP |
Kainic Acid results in decreased expression of VAMP7 mRNA |
CTD |
PMID:19700661 |
|
NCBI chr12:18,996,566...19,033,714
Ensembl chr12:18,996,591...19,030,381
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases expression |
ISO |
Kainic Acid results in decreased expression of VEGFA mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
G |
Wfs1 |
wolframin ER transmembrane glycoprotein |
increases expression |
ISO |
Kainic Acid results in increased expression of WFS1 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr14:78,640,707...78,665,224
Ensembl chr14:78,640,620...78,665,966
|
|
G |
Xpa |
XPA, DNA damage recognition and repair factor |
increases expression |
EXP |
Kainic Acid results in increased expression of XPA mRNA |
CTD |
PMID:19700661 |
|
NCBI chr 5:61,749,767...61,793,641
Ensembl chr 5:61,749,767...61,792,928
|
|
G |
Zcchc7 |
zinc finger CCHC-type containing 7 |
increases expression |
ISO |
Kainic Acid results in increased expression of ZCCHC7 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 5:60,250,546...60,430,119
Ensembl chr 5:60,250,546...60,429,708
|
|
|
G |
Mr1 |
major histocompatibility complex, class I-related |
affects expression |
ISO |
Lincomycin affects the expression of MR1 mRNA |
CTD |
PMID:25811541 |
|
NCBI chr13:72,771,992...72,789,861
Ensembl chr13:72,771,984...72,789,841
|
|
G |
RT1-S3 |
RT1 class Ib, locus S3 |
affects expression |
ISO |
Lincomycin affects the expression of HLA-E mRNA |
CTD |
PMID:25811541 |
|
NCBI chr20:3,176,124...3,180,825
Ensembl chr20:3,176,107...3,179,818
|
|